company background image
SZD logo

Santen Pharmaceutical DB:SZD Stock Report

Last Price

€9.40

Market Cap

€3.2b

7D

-8.7%

1Y

8.0%

Updated

19 Dec, 2024

Data

Company Financials +

Santen Pharmaceutical Co., Ltd.

DB:SZD Stock Report

Market Cap: €3.2b

SZD Stock Overview

Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. More details

SZD fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends5/6

Rewards

Trading at 54.2% below our estimate of its fair value

Earnings are forecast to grow 11.51% per year

Pays a reliable dividend of 2.2%

Analysts in good agreement that stock price will rise by 35.4%

Risk Analysis

Large one-off items impacting financial results


My Notes

Capture your thoughts, links and company narrative

Santen Pharmaceutical Co., Ltd. Competitors

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€302.2m

Merck KGaA

XTRA:MRK

€60.2b

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of share price highs, lows and changes for Santen Pharmaceutical
Historical stock prices
Current Share PriceJP¥9.40
52 Week HighJP¥11.80
52 Week LowJP¥8.60
Beta0.21
1 Month Change-5.05%
3 Month Change-13.76%
1 Year Change8.05%
3 Year Change-11.32%
5 Year Change-43.37%
Change since IPO141.40%

Recent News & Updates

Recent updates

Shareholder Returns

SZDDE PharmaceuticalsDE Market
7D-8.7%-3.9%-2.6%
1Y8.0%-15.2%7.1%

Return vs Industry: SZD exceeded the German Pharmaceuticals industry which returned -13.7% over the past year.

Return vs Market: SZD matched the German Market which returned 8% over the past year.

Price Volatility

Is SZD's price volatile compared to industry and market?
SZD volatility
SZD Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.5%

Stable Share Price: SZD has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: SZD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18903,744Takeshi Itowww.santen.com

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.

Santen Pharmaceutical Co., Ltd. Fundamentals Summary

How do Santen Pharmaceutical's earnings and revenue compare to its market cap?
SZD fundamental statistics
Market cap€3.25b
Earnings (TTM)€159.83m
Revenue (TTM)€1.85b

20.3x

P/E Ratio

1.8x

P/S Ratio

Is SZD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SZD income statement (TTM)
RevenueJP¥302.56b
Cost of RevenueJP¥127.31b
Gross ProfitJP¥175.26b
Other ExpensesJP¥149.13b
EarningsJP¥26.12b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 06, 2025

Earnings per share (EPS)76.25
Gross Margin57.92%
Net Profit Margin8.63%
Debt/Equity Ratio0%

How did SZD perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

68%

Payout Ratio

Does SZD pay a reliable dividends?

See SZD dividend history and benchmarks
When do you need to buy SZD by to receive an upcoming dividend?
Santen Pharmaceutical dividend dates
Ex Dividend DateMar 28 2025
Dividend Pay DateJun 26 2025
Days until Ex dividend97 days
Days until Dividend pay date187 days

Does SZD pay a reliable dividends?

See SZD dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 12:13
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santen Pharmaceutical Co., Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Philip HallBNP Paribas Securities (Asia)
Koichi MameganoBofA Global Research